Can Weight-Loss Injections Affect The Kidneys And Liver?

Weight-loss injections are not medicines that directly damage the kidneys and liver in every user. However, fluid loss caused by nausea, vomiting and diarrhoea may negatively affect kidney function. Regarding the liver, the person’s existing liver disease, other medicines, alcohol consumption, gallbladder problems and rapid weight loss should be assessed together.

Current product information for medicines containing semaglutide and tirzepatide identifies acute kidney injury due to volume depletion as one of the main kidney-related risks. Kidney function should be monitored particularly in people experiencing severe or prolonged gastrointestinal adverse effects.

Conditions of use in people with hepatic impairment may differ according to the product. Although standard dose adjustment may not be required for some products in mild or moderate hepatic impairment, experience in severe hepatic impairment is limited. Starting or continuing a weight-loss injection therefore requires an individual medical assessment.

How Can Weight-Loss Injections Affect The Kidneys?

Weight-loss injections are not considered classically nephrotoxic medicines that directly damage the kidneys. The main kidney-related risk is usually associated with insufficient fluid intake caused by nausea, vomiting, diarrhoea and appetite loss.

When the amount of fluid in the body decreases significantly, blood flow to the kidneys may fall. This may result in increased creatinine and temporary or more serious impairment of kidney filtration. Product information for semaglutide and tirzepatide states that kidney function should be monitored in patients experiencing adverse effects that may lead to volume depletion.

The risk may be higher particularly in people who:

• Have pre-existing chronic kidney disease

• Are older

• Experience recurrent vomiting or diarrhoea

• Have significantly reduced daily fluid intake

• Use diuretic medicines

• Use certain blood pressure medicines

• Use other medicines that may affect the kidneys

• Lose fluids because of fever or infection

• Experience severe digestive adverse effects after dose escalation

The presence of one of these risks does not necessarily mean that a weight-loss injection cannot be used. However, closer monitoring may be needed at the beginning of treatment and during periods of adverse effects.

How Does Dehydration Affect The Kidneys?

Medicines such as semaglutide, liraglutide and tirzepatide may cause nausea, vomiting, diarrhoea and reduced appetite in some people. Both reduced fluid consumption and fluid loss through vomiting or diarrhoea increase the risk of dehydration.

The liraglutide product information published by the Turkish Medicines and Medical Devices Agency states that signs and symptoms of dehydration, including renal impairment and acute kidney failure, have been reported in people treated with GLP-1 receptor agonists. Patients should be informed about the potential risk of fluid loss associated with gastrointestinal adverse effects.

Possible signs of dehydration include:

• Dry mouth and tongue

• Intense thirst

• Dark urine

• Reduced urine output

• Dizziness when standing

• Palpitations

• Significant weakness

• Dry skin

• Inability to consume fluids

• Feeling faint

A routine appointment should not be awaited when these symptoms occur, particularly together with vomiting or diarrhoea.

Can People With Kidney Disease Use Weight-Loss Injections?

Chronic kidney disease does not necessarily mean that every weight-loss injection is prohibited. Some semaglutide and tirzepatide product information states that medicine exposure is not substantially altered in mild, moderate or severe renal impairment and that standard dose adjustment is not required solely on the basis of kidney function. However, experience in end-stage kidney disease is limited for certain products.

The following should also be assessed in people with kidney disease:

• Current creatinine and estimated glomerular filtration rate

• Stage of kidney disease

• Presence of protein or albumin in the urine

• Blood pressure

• Sodium and potassium levels

• Blood pressure medicines and diuretics

• Any daily fluid restriction

• Dialysis treatment

• Heart failure or oedema

• Previous acute kidney injury

People following a fluid restriction because of chronic kidney or heart disease should not increase fluid intake based on general internet advice. Their daily fluid allowance should be determined according to their individual health status.

Which Kidney Tests May Be Performed During Treatment?

The same kidney tests do not need to be performed at the same intervals for every user. The scope of testing depends on baseline kidney function, other medicines, adverse effects and accompanying conditions.

A physician may assess:

• Creatinine: One of the main blood values providing information about kidney filtration.

• Estimated Glomerular Filtration Rate: Helps assess the kidneys’ ability to filter blood.

• Urea: May provide additional information about kidney function and fluid status.

• Sodium And Potassium: May be affected by vomiting, diarrhoea, dehydration and other medicines.

• Urinalysis: May show blood, protein, infection or another urinary problem.

• Urinary Albumin Or Protein: May be assessed in people with diabetes or chronic kidney disease.

Not all these tests are routinely required for everyone using weight-loss injections. The NICE guide on weight-management medicines also recommends planning kidney and liver function tests according to the person’s clinical history and current health.

What Does An Increase In Creatinine Mean?

An increase in creatinine does not by itself show that the weight-loss injection has caused permanent kidney damage. Insufficient fluid intake, vomiting, diarrhoea, fever, intense exercise, certain medicines and other kidney conditions may also affect creatinine.

The following information is important when interpreting the result:

• Previous creatinine values

• Estimated glomerular filtration rate

• Recent fluid intake

• Presence of vomiting or diarrhoea

• Urine output

• Other medicines

• Blood pressure

• Presence of fever or infection

When creatinine increases, the person should not reduce the dose or suddenly stop the weight-loss injection without medical advice. The physician should assess fluid status, other medicines and kidney function together.

Do Weight-Loss Injections Damage The Liver?

Current product information does not generally describe weight-loss injections as medicines that commonly cause direct liver injury. However, when liver test results change, it should not automatically be assumed that the medicine is responsible.

Liver enzymes may increase because of:

• Metabolic dysfunction-associated fatty liver disease

• Alcohol consumption

• Viral hepatitis

• Gallstones or bile duct obstruction

• Other medicines

• Herbal products and nutritional supplements

• Rapid weight loss

• Intense exercise or muscle injury

• Other liver and biliary diseases

Product information evaluating the pharmacokinetics of semaglutide and tirzepatide in people with mild, moderate and severe hepatic impairment states that there was no substantial change requiring dose adjustment. However, careful assessment is needed because clinical experience in severe liver disease is limited.

Can People With Fatty Liver Disease Use Weight-Loss Injections?

Obesity, insulin resistance and type 2 diabetes may occur together with fatty liver disease. Weight loss and improved metabolic control may help improve values associated with fatty liver disease in some people. However, this does not mean that every weight-loss injection treats every form of liver disease.

The following may be assessed in people with fatty liver disease:

• ALT and AST

• Gamma-glutamyl transferase

• Alkaline phosphatase

• Bilirubin

• Platelet count

• Blood glucose and HbA1c

• Blood lipids

• Liver ultrasound

• Risk of liver fibrosis

• Alcohol consumption

• Medicines and supplements

When liver enzymes are markedly elevated, jaundice is present or advanced liver disease is suspected, a detailed assessment may be required before weight-loss treatment is started.

Can Weight-Loss Injections Be Used In Liver Failure?

The severity and cause of hepatic impairment directly affect the treatment decision. Standard dose adjustment may not be required for some products in mild or moderate liver impairment. However, experience in severe hepatic impairment is limited, and some semaglutide product information does not recommend use in severe liver impairment.

People with cirrhosis or advanced liver disease may also experience:

• Fluid accumulation in the abdomen

• Leg swelling

• Nutritional deficiency

• Muscle loss

• Increased bleeding tendency

• Altered consciousness

• Impaired kidney function

• Changes in the metabolism of medicines

Weight loss should therefore not always be interpreted as a positive development in advanced liver disease. Reduced appetite, rapid weight loss and muscle loss may worsen health. Treatment should be planned through multidisciplinary assessment.

Can Gallbladder Problems Affect Liver Tests?

One issue that should be assessed regarding the liver during weight-loss injection treatment is the gallbladder and biliary tract. Cases of gallstones and gallbladder inflammation have been reported in product information for semaglutide, liraglutide and tirzepatide. Rapid and substantial weight loss may also increase the risk of gallstones.

When a gallstone blocks the bile duct, bilirubin, alkaline phosphatase and gamma-glutamyl transferase may increase. In this situation, the problem may be an obstruction to bile flow rather than direct medicine-induced injury to liver cells.

Symptoms of gallbladder or biliary disease may include:

• Pain in the upper-right abdomen

• Pain that increases after fatty meals

• Pain radiating to the back or right shoulder

• Nausea and vomiting

• Fever

• Yellowing of the skin and eyes

• Dark urine

• Pale stools

• Itchy skin

A routine appointment should not be awaited when these symptoms occur. The physician may plan ultrasound and relevant laboratory tests when gallstones are suspected.

Can Pancreatic Problems Affect Kidney And Liver Values?

Acute pancreatitis may cause severe abdominal pain, vomiting and dehydration. Significant fluid loss may affect kidney function, while liver and biliary tests may change in pancreatitis caused by gallstones.

Product information for GLP-1- and GLP-1/GIP-based medicines includes warnings regarding acute pancreatitis. Severe and persistent abdominal pain that may radiate to the back, particularly when accompanied by nausea or vomiting, requires medical assessment without waiting for a routine medicine review.

It should not be assumed that everyone without symptoms requires routine amylase or lipase testing. The need for testing should be determined according to symptoms, medical history and examination findings.

Which Liver Tests May Be Performed During Treatment?

Liver function and the biliary tract are evaluated through different laboratory values. The necessary tests vary according to the person’s health history.

Tests that may be assessed include:

• ALT: One of the tests sensitive to liver-cell injury.

• AST: May also be affected by muscle and other tissues.

• Gamma-Glutamyl Transferase: May be affected by the biliary tract, alcohol use and certain medicines.

• Alkaline Phosphatase: May rise in biliary disease and may also be affected by bone conditions.

• Total And Direct Bilirubin: Provides information about bile flow and the liver’s processing capacity.

• Albumin: May help assess the liver’s protein-production capacity.

• Prothrombin Time Or INR: May be used to assess clotting function in advanced liver disease.

• Full Blood Count: May provide additional information about advanced liver disease and nutritional status.

A mild increase in ALT or AST does not by itself mean that treatment should be stopped. The degree of elevation, previous results, symptoms, alcohol consumption, other medicines and imaging findings should be considered together.

Can Rapid Weight Loss Affect The Kidneys And Liver?

Very rapid weight loss may cause health problems when accompanied by severe appetite reduction, inadequate nutrition and insufficient fluid intake. Inadequate fluid may affect kidney function, while rapid weight loss may increase the risk of gallstones.

Possible problems related to rapid weight loss include:

• Loss of muscle mass

• Fatigue and dizziness

• Dehydration

• Electrolyte imbalance

• Constipation

• Gallstones

• Vitamin and mineral deficiencies

• Hair loss

• Excessive reduction in blood pressure

The speed of weight loss is not the only measure of success. Adequate protein, energy, fluid, vitamin and mineral intake should be maintained during treatment.

Can Alcohol Increase The Risk?

Alcohol is metabolised by the liver and excessive use may increase the risk of fatty liver disease, elevated liver enzymes and pancreatitis. Consuming alcohol together with nausea, vomiting or low food intake caused by a weight-loss injection may worsen dehydration, dizziness and blood glucose fluctuations.

Alcohol use should be assessed particularly in people with liver disease, previous pancreatitis, elevated triglycerides, diabetes or recurrent vomiting. Alcohol consumption will be discussed in greater detail in the article titled “Can Alcohol Be Consumed While Using Weight-Loss Injections?”

Are Herbal Products And Supplements Safe?

Products marketed for “liver cleansing”, “reducing water retention” or “fat burning” should not be assumed to be safe when combined with a weight-loss injection. Certain herbal products may cause liver injury, electrolyte disturbances, diarrhoea or dehydration.

The physician should be informed about products such as:

• Weight-loss teas

• Herbal laxatives

• Diuretic supplements

• High-dose green tea extracts

• Multi-ingredient fat-burning products

• High-dose vitamins and minerals

• Sports supplements

• Online products without clearly stated ingredients

The word “natural” does not mean that a product is safe for the kidneys and liver. All prescription medicines, non-prescription products and supplements should be reported to the physician.

How Often Should Kidney And Liver Values Be Checked?

There is no fixed testing interval for everyone using weight-loss injections. The frequency of monitoring depends on baseline values, kidney or liver disease, other medicines and adverse effects.

Closer monitoring may be considered when there is:

• Pre-existing kidney disease

• Elevated liver enzymes

• Fatty liver disease or cirrhosis

• Recurrent vomiting or diarrhoea

• Older age

• Diuretic use

• Heart failure

• Previous gallstones

• High alcohol consumption

• A dose-escalation period

• Rapid weight loss

• A newly started medicine or supplement

The NICE follow-up guide states that the monitoring plan should be personalised according to the person’s clinical circumstances and that previous test results may be used when obtained within an appropriate timeframe.

Should The Medicine Be Stopped When Kidney Or Liver Values Worsen?

Not every change in laboratory values means that the weight-loss injection should immediately be stopped. The cause, severity and relationship with symptoms should first be assessed.

The physician may consider:

• Repeating tests within a short period

• Assessing dehydration

• Reviewing other medicines

• Requesting urine or imaging tests

• Postponing dose escalation

• Temporarily interrupting treatment

• Changing to a different treatment

• Referring to nephrology, gastroenterology or another specialty

Stopping, interrupting or changing the dose is not a decision the person should make independently. Regular medicines that may affect kidney or liver values should also not be stopped without medical advice.

Which Symptoms Require Medical Assessment?

The following symptoms may require prompt assessment for kidney, liver, biliary or pancreatic problems:

• Significant reduction in urine output

• Inability to urinate for a prolonged period

• Recurrent or persistent vomiting

• Inability to consume fluids

• Severe and persistent abdominal pain

• Abdominal pain radiating to the back

• Severe pain in the upper-right abdomen

• Yellowing of the skin or eyes

• Dark urine

• Pale stools

• High fever with abdominal pain

• Significant swelling of the legs or face

• Confusion

• Fainting

• Rapidly worsening general health

In cases of severe shortness of breath, altered consciousness, seizure, fainting or rapidly worsening general health, an online consultation or routine follow-up should not be awaited. Emergency services should be contacted or the nearest emergency department should be visited.

This content is provided for general informational purposes. The selection, initiation, dose, monitoring and discontinuation of weight-loss injections require an individual medical assessment.

Plan Your Online Endocrinology Doctor Consultation With Happ Health

With the “Health Everywhere, For Everyone, Always.” approach, we believe that weight-loss injection treatment should involve assessing not only changes in weight but also kidney and liver function, fluid status, other medicines and accompanying conditions.

By planning an Online Endocrinology Doctor consultation through Happ Health, you can have your history of kidney and liver disease, medicines, adverse effects and recent test results assessed. An endocrinologist may determine which tests, including creatinine, estimated glomerular filtration rate, electrolytes and liver enzymes, are necessary according to your individual risks.

Preparing your recent blood and urine test results, list of medicines and supplements, previous ultrasound reports and the onset of your symptoms before the online consultation may make the assessment easier. When a physical examination, ultrasound, advanced laboratory testing or another specialist assessment is required, you may be referred to an in-person healthcare institution.

In cases of severe and persistent abdominal pain, recurrent vomiting, inability to consume fluids, significantly reduced urine output, jaundice, fainting, altered consciousness or rapidly worsening general health, an online follow-up should not be awaited and a healthcare institution should be contacted.

References

• Turkish Medicines And Medical Devices Agency, Wegovy Summary Of Product Characteristics:
  https://www.titck.gov.tr/storage/Archive/2025/kubKtAttachments/WEGOVY0.5KB_17_02_2025.pdf

• Turkish Medicines And Medical Devices Agency, Saxenda Summary Of Product Characteristics:
  https://www.titck.gov.tr/storage/Archive/2025/kubKtAttachments/saxendakubtemiz_10_03_2025.pdf

• Turkish Medicines And Medical Devices Agency, Mounjaro Summary Of Product Characteristics:
  https://www.titck.gov.tr/storage/Archive/2025/kubKtAttachments/MOUNJARO10KBONAY_31_10_2025.pdf

• U.S. Food And Drug Administration, Current Wegovy Prescribing Information:
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf

• U.S. Food And Drug Administration, Current Zepbound Prescribing Information:
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf

• European Medicines Agency, Wegovy Product Information:
  https://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5422-en_3.pdf

• European Medicines Agency, Ozempic Product Information:
  https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf

• National Institute For Health And Care Excellence, Safe Prescribing And Monitoring Of Weight-Management Medicines:
  https://www.nice.org.uk/guidance/ta1026/resources/a-practical-guide-to-using-medicines-to-manage-overweight-and-obesity-pdf-19828318651333